Navigation Links
Luoxis Establishes Study Collaborations with Two Research Centers in Oxidative Stress
Date:1/6/2014

rtable analyzer and disposable sensors that rapidly measure the level of oxidative stress and antioxidant reserves in biologic specimens via assessment of oxidation-reduction potential (ORP). ORP has been shown to be an important measure in both critical and chronic illnesses and is a novel marker of patient morbidity across a wide range of conditions. There are numerous clinical indications for this homeostatic parameter for which there is no currently available test. Luoxis is a majority-owned subsidiary of Ampio Pharmaceuticals, Inc.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statement
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Investor Contact:
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
2. Ampio forms Luoxis Diagnostics to Commercialize ORP Technology
3. Quantum Materials Establishes Milestone as First Company to Deliver Tetrapod Quantum Dot Samples to LCD Display Manufacturer
4. Texas Childrens Hospital establishes the Jeffrey Modell Diagnostic & Research Center with a donation from the Jeffrey Modell Foundation
5. PA Governor Corbett: Americure Rx Establishes Operations in Lehigh Valley; Creates 51 Jobs
6. Winterhawk Consulting Establishes Partnership with Onapsis Inc to expand their SAP security offerings using Onapsis X1.
7. ICV Partners Establishes Dialysis Treatment Platform With Acquisition Of Atlantis Healthcare Group Puerto Rico, Inc.
8. Life Technologies Establishes International Influenza Network
9. H. D. Smith Establishes Specialty Solutions Organization And Realigns Senior Leadership To Support Growing Geographic Reach, Diversified Businesses
10. PQ Bypass Graduates from the Fogarty Institute for Innovation, Establishes Independent Operations
11. HYCOR Establishes Center Of Operations In Kassel, Germany To Provide Dedicated Support To European Distributors And Customers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
(Date:7/30/2015)... Global ENT (Ear, Nose, ... USD 23.01 million in 2022, according to a new ... geriatric population, increasing prevalence of ear, nose, and throat ... among target customer base are expected serve this market ... According to estimates published by the WHO, 15% of ...
(Date:7/30/2015)... 2015  NanoSmart Pharmaceuticals, Inc., a private pharmaceutical ... Orphan Drug Designation from the Food and Drug ... uses NanoSmart,s proprietary drug delivery platform. The drug ... treatment of Ewing,s sarcoma, a rare type of ... Drug Designation on the basis of a plausible ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... Nutri-Force Nutrition is proud to announce the ... Miami Lakes, Florida. This new facility was designed ... customers with industry-leading quality and exceptionally efficient manufacturing ... innovative production control processes, the new facility includes ...
... 10 Stryker Corporation (NYSE: SYK ) announced ... held, software technology firm. OtisMed will focus on ... many benefits that surgeons and patients realize from Stryker,s ... OtisMed will operate as part of Stryker,s Orthopaedics Division ...
Cached Medicine Technology:Stryker Announces Agreements To Acquire Assets 2Stryker Announces Agreements To Acquire Assets 3
(Date:7/30/2015)... County, CA (PRWEB) , ... July 30, 2015 ... ... home health care throughout Orange, Riverside, Los Angeles, and San Bernardino counties, today ... as the new Palliative Care Administrator. Dr. Demoratz is a strong proponent of ...
(Date:7/30/2015)... Orange County, CA (PRWEB) , ... July 30, 2015 , ... ... Orange County, Los Angeles, Riverside, and San Bernardino, recently announced that the Centers for ... a new rating system of home health care providers. 24/7 Care At Home’s agency ...
(Date:7/30/2015)... Huntington Beach, CA (PRWEB) , ... ... ... Nursing Center recently released a video, “Beachside Nursing Center,” to announce its ... satisfaction and five-star ratings. Beachside's administrator and staff members support the CMS ...
(Date:7/30/2015)... ... July 30, 2015 , ... The need for accessibility is never greater ... comfort to patients as well as visiting friends and family during these critical moments, ... , The stations - powered by ChargeItSpot , a Philadelphia-based startup that recently ...
(Date:7/30/2015)... ... 30, 2015 , ... The Beryl Institute announces its sixth ... with Patient Experience Institute, these offerings reinforce the commitment to help frame and ... throughout the experience movement, and provide information and research to support expanded focus ...
Breaking Medicine News(10 mins):Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Beachside Nursing Center Releases New Video 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3
... Cancer Genome Atlas (TCGA) has reported results from its ... cancer glioblastoma. , The findings are reported in the ... , The TCGA team, comprised of more than 100 ... the country, analyzed 601 genes in tumor samples from ...
... probability of someone cheating during the course of a relationship ... Genevive Beaulieu-Pelletier, PhD student at the Universit de Montral,s Department ... we get married with the best of intentions things don,t ... about infidelity is why people are willing to conduct themselves ...
... spend $1M a day sponsoring campus events, giveaways, lung ... Fewer U.S. college students (1 in 5) are smoking ... need to take a stand against aggressive tobacco industry ... a new American Lung Association report finds. , ...
... Sutter Health Partners, Wellness Program Proves Cost-Saving for Employers ... and Life-Saving for Employees, ... five months. Donna Rosenbusch, R.N., is completing triathlons. Marcia,Augsburger is seeing ... and staff at the law firm where she is a,partner. And ...
... Parents probably,wouldn,t have guessed, but kids like soyfoods. ... soyfoods as much as meat,counterparts. The trick -- ... soyfoods., A plate waste study, funded by ... macaroni & cheese, burgers, chicken nuggets, and,chicken Caesar ...
... $ 885 thousand, 400 thousand) for each of ... by the winners to research projects , Milan, 8 September ... were announced today in a public event: , ... Visual Arts since 1700, Thomas Nagel (USA), University of New ...
Cached Medicine News:Health News:The Cancer Genome Atlas reports first results, Johns Hopkins Kimmel Cancer Center collaborates 2Health News:Infidelity dissected: New research on why people cheat 2Health News:Fewer College Kids Smoking, But Industry Tactics a Threat 2Health News:Fewer College Kids Smoking, But Industry Tactics a Threat 3Health News:'Live Well for Life' Benefits Companies and Workers 2Health News:'Live Well for Life' Benefits Companies and Workers 3Health News:'Live Well for Life' Benefits Companies and Workers 4Health News:Back to School With Soy 2Health News:Balzan Foundation announced 2008 prize winners 2Health News:Balzan Foundation announced 2008 prize winners 3
Immuno-turbidimetric Assay for Protein S Antigen. Suspension of microlatex particles coated with specific antibodies....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~8.8 moles/vial and bovine factorXa ~2.2 ...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor XI Assay by STA© Analyzers. Freeze-dried human plasma lacking factor XI....
Medicine Products: